Key result
A MAOI-tricyclic antidepressant combination in oral therapeutic doses was safe, with the incidence and severity of side effects essentially the same as those seen in control groups.
Why the study?
Does a monoamine oxidase inhibitor (MAOI)-tricyclic antidepressant combination increase side effects compared to control groups in patients requiring antidepressants?
Observational (n=201)
Does a monoamine oxidase inhibitor (MAOI)-tricyclic antidepressant combination increase side effects compared to control groups in patients requiring antidepressants?
The combination of MAOI and tricyclic antidepressants in oral therapeutic doses appears safe, though orthostatic hypotension is common and overdose toxicity remains a concern.
Supports observational safety of MAOI-tricyclic combination; leaves open confirmation in randomized trials before clinical adoption.
The charts of 150 inpatients and 51 outpatients treated with a monoamine oxidase inhibitor (MAOI)-tricyclic antidepressant combination were reviewed. The incidence and severity of side effects among the patients on the combined regimen were essentially the same as those seen in the control groups. There were no deaths or strokes resulting from use of this regimen. The most frequent troublesome side effect was orthostatic hypotension. We conclude that the use of a MAOI-tricyclic combination in oral therapeutic doses is safe. However, the efficacy of this combination has not yet been proved, and it may be particularly toxic if taken in an overdose.
No takes yet. Share an insight, caveat, or question.
Duane G. Spiker (1976) reported an observational. MAOI-tricyclic antidepressant combination vs. Control groups was evaluated on Incidence and severity of side effects. A MAOI-tricyclic antidepressant combination in oral therapeutic doses was safe, with the incidence and severity of side effects essentially the same as those seen in control groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: